Discovery of Potent and Oral Bioavailable MAT2A Inhibitors for the Treatment of MTAP-Deleted Tumors

被引：3
|
作者：
Li, Qun [1 ]
Zang, Yang [1 ]
An, Dan [1 ]
Liu, Lifei [1 ]
Jiang, Wen [1 ]
Liu, Rongchen [1 ]
Su, Jiangtao [2 ]
Yang, Jun [1 ,3 ,4 ]
Li, Lie [1 ]
Zhang, Xuejun [1 ]
机构：
[1] Hubei Biopharmaceut Ind Technol Inst Inc, Wuhan 430075, Hubei, Peoples R China
[2] Hubei Univ Technol, Wuhan 430068, Peoples R China
[3] Humanwell Healthcare Grp Co Ltd, Wuhan 430075, Hubei, Peoples R China
[4] Humanwell Pharmaceut US Inc, Ballwin, MO 63011 USA
来源：
ACS MEDICINAL CHEMISTRY LETTERS | 2023年 / 14卷 / 12期
关键词：
Allosteric Inhibitor; Methionine Adenosyltransferase2A (MAT2A); Methylthioadenosine Phosphorylase (MTAP); 5'-Methylthioadenosine (MTA); 3H-Pyrido[1,2-c]pyrimidin-3-one; METHYLTRANSFERASE; METHIONINE;
D O I：
10.1021/acsmedchemlett.3c00488
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Inhibition of methionine adenosyltransferase 2A (MAT2A) has received significant interest because of its implication as a synthetic lethal target in methylthioadenosine phosphorylase (MTAP)-deleted cancers. Here, we report the discovery of a series of 3H-pyrido-[1,2-c]-pyrimidin-3-one derivatives as novel MAT2A inhibitors. The selected compound 30 exhibited high potency for MAT2A inhibition and a favorable pharmacokinetic profile. Furthermore, in an HCT-116 MTAP-deleted xenograft model, compound 30 showed better in vivo potency than current clinical compound AG-270.
引用
收藏
页码：1876 / 1881
页数：6
相关论文
共 50 条
  • [41] Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2
    Nguyen, Minh H.
    Atasoylu, Onur
    Wu, Liangxing
    Kapilashrami, Kanishk
    Pusey, Michelle
    Gallagher, Karen
    Lai, Cheng-Tsung
    Zhao, Peng
    Barbosa, Joseph
    Liu, Kai
    He, Chunhong
    Zhang, Colin
    Styduhar, Evan D.
    Witten, Michael R.
    Chen, Yaoyu
    Lin, Luping
    Yang, Yan-ou
    Covington, Maryanne
    Diamond, Sharon
    Yeleswaram, Swamy
    Yao, Wenqing
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, : 1159 - 1164
  • [42] Discovery of orally bioavailable phosphonate prodrugs of potent ENPP1 inhibitors for cancer treatment
    Gao, Shanyun
    Hou, Yingjie
    Xu, Yanxiao
    Li, Jingjing
    Zhang, Chaobo
    Jiang, Shujuan
    Yu, Songda
    Liu, Lei
    Tu, Wangyang
    Yu, Bing
    Zhang, Yixiang
    Li, Leping
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 279
  • [43] Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability
    Zhang, Silong
    Qing, Luolong
    Wang, Ziwei
    Zhang, Yu
    Li, Yuanyuan
    Fang, Huaxiang
    Liu, Yi
    He, Huan
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (07) : 4849 - 4867
  • [44] Discovery of Clinical Candidate NTQ1062 as a Potent and Bioavailable Akt Inhibitor for the Treatment of Human Tumors
    Ma, Changyou
    Wu, Jian
    Wang, Lei
    Ji, Xiaojun
    Wu, Yebin
    Miao, Lei
    Chen, Donghui
    Zhang, Linlin
    Wu, Youzhi
    Feng, Haiwei
    Tang, Ying
    Zhou, Qiuhua
    Pei, Junjie
    Yang, Xule
    Xu, Dan
    You, Qidong
    Xie, Yuan
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (12) : 8144 - 8168
  • [45] PH020-2: an MTA-cooperative PRMT5 inhibitor with excellent selectivity and brain-penetration capability that targets MTAP-deleted tumors
    Gao, Feng
    Liu, Bin
    Wang, Jing
    Jing, Liandong
    Wu, Yongyong
    Zhang, Pengzhi
    Gao, Yu
    Li, Zhizhong
    Guo, Yongqi
    CANCER RESEARCH, 2024, 84 (06)
  • [46] A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion
    Johnson, M. L.
    Rodon, J.
    Aljumaily, R.
    Villalona-Calero, M.
    Borazanci, E.
    Pishvaian, M.
    Turk, A.
    Carvajal, R. D.
    Mantia, C.
    Giaccone, G.
    Mounir, Z.
    Patel, A.
    Maurer, M.
    Neilan, C.
    Rajendran, D.
    Ganesan, U.
    Hinkle, J.
    Tolcher, A. W.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S766 - S767
  • [47] Discovery of 5-Azaquinoxaline Derivatives as Potent and Orally Bioavailable Allosteric SHP2 Inhibitors
    Elsayed, Mohamed S. A.
    Blake, James F.
    Boys, Mark L.
    Brown, Eric
    Chapsal, Bruno D.
    Chicarelli, Mark J.
    Cook, Adam W.
    Fell, Jay B.
    Fischer, John P.
    Hanson, Lauren
    Lemieux, Christine
    Martinson, Matthew C.
    McCown, Joseph
    McNulty, Oren T.
    Mejia, Macedonio J.
    Neitzel, Nickolas A.
    Otten, Jennifer N.
    Rodriguez, Martha E.
    Wilcox, Daniel
    Wong, Christina E.
    Zhou, Yeyun
    Hinklin, Ronald J.
    ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (12): : 1673 - 1681
  • [48] Discovery of Isoindoline Amide Derivatives as Potent and Orally Bioavailable ADAMTS-4/5 Inhibitors for the Treatment of Osteoarthritis
    Zhao, Peng
    Liu, Dong
    Song, Chunying
    Li, Di
    Zhang, Xinzhu
    Horecny, Ivana
    Zhang, Fengqi
    Yan, Yuna
    Zhuang, Linghang
    Li, Jing
    Liu, Suxing
    Mao, Yuchang
    Feng, Jun
    Liu, Jian
    Tao, Weikang
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2022, : 458 - 467
  • [49] Discovery of Potent and Orally Bioavailable Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for the Treatment of Osteosarcoma
    Chen, Xiaojing
    Liu, Lu
    Liu, Peng
    Chen, Yingying
    Lin, Dan
    Yan, Hao
    Yan, Qi
    Wang, Yi
    Qiu, Yinda
    Fang, Bo
    Huang, Huijing
    Qian, Jianchang
    Zhao, Yunjie
    Du, Zhou
    Zhang, Qianwen
    Li, Xiaokun
    Zheng, Xiaohui
    Liu, Zhiguo
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (07) : 5374 - 5391
  • [50] Discovery of Highly Selective, Potent, Covalent, and Orally Bioavailable Factor XIIa Inhibitors for the Treatment of Thrombo-Inflammation
    Meng, Zhiwei
    Wang, Shengnan
    Chen, Fangrong
    Zhang, Zhenzhen
    Zhang, Yajing
    Yin, Zequn
    Duan, Yajun
    Zheng, Nan
    Wang, Qin
    Liao, Chenzhong
    Chen, Yuanli
    Xie, Zhouling
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, : 10946 - 10966
12345